Curran Terrie
Curran Terrie, DIR, reported a transaction classified as exercise at Arcutis Biotherapeutics, Inc. involving 1072.000000 shares for an estimated $0.00. Reported holdings after the transaction were 11148.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Aug 20, 2026
- Filing date
- Aug 24, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
ARQT price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001628280-26-058648 Stock Option (right to buy)
- Transaction date
- Aug 20, 2026 Filed Aug 24, 2026, 08:19 PM · 4d delay
- Shares
- 1,072 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 11,148 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-10 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
- F2
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228, inclusive. The Reporting Person hereby underta…
- F3
The option is fully vested.
0 other transactions
0 recent txs